+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilars Market by Product Type (Erythropoietin, Follitropin, Granulocyte-Colony Stimulating Factor (G-CSF)), Indication (Autoimmune Diseases, Blood Disorders, Diabetes), Administration Route, End User - Global Forecast 2025-2030- Product Image
Biosimilars Market by Product Type (Erythropoietin, Follitropin, Granulocyte-Colony Stimulating Factor (G-CSF)), Indication (Autoimmune Diseases, Blood Disorders, Diabetes), Administration Route, End User - Global Forecast 2025-2030- Product Image
Sale

Biosimilars Market by Product Type (Erythropoietin, Follitropin, Granulocyte-Colony Stimulating Factor (G-CSF)), Indication (Autoimmune Diseases, Blood Disorders, Diabetes), Administration Route, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083156
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The biosimilars market is undergoing rapid transformation, driven by regulatory changes, technological advances, and evolving stakeholder demands. Senior decision-makers navigating this sector will benefit from a data-driven overview highlighting both challenges and new opportunities emerging across global healthcare settings.

Market Snapshot: Unlocking Growth in the Biosimilars Market

The Biosimilars Market grew from USD 31.83 billion in 2024 to USD 35.27 billion in 2025. It is expected to continue growing at a CAGR of 11.32%, reaching USD 60.60 billion by 2030. These gains are being shaped by biosimilars' expanding global reach and acceptance, as well as innovations in manufacturing, regulatory alignment, and market access strategies. The market is responding to competitive pricing, payer-driven adoption, and a shift toward patient-centric care, particularly in oncology and chronic disease management.

Biosimilars Market Scope & Segmentation

This report provides a comprehensive analysis across product categories, therapeutic applications, administration routes, end-user channels, and geographic regions, offering actionable insights that matter to strategic planners.

  • Product Types: Erythropoietin, Follitropin, Granulocyte-Colony Stimulating Factor (G-CSF), Human Growth Hormone, Insulin, Interferons, Monoclonal Antibodies (mAbs)
  • Indications: Autoimmune Diseases, Blood Disorders, Diabetes, Growth Hormone Deficiency, Infectious Diseases, Oncology
  • Administration Routes: Intramuscular, Intravenous, Subcutaneous
  • End Users: Clinics, Homecare settings, Hospitals
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe/Middle East/Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, and others), Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Companies: Alvotech S.A, Amgen Inc., Apotex Inc., Biocon Limited, BioFactura, Biogen Inc., Boehringer Ingelheim International, Catalent, Celltrion Healthcare, Coherus BioSciences, Dr. Reddy's Laboratories, Eden Biologics, F. Hoffmann-La Roche AG, Fresenius Kabi, Innovent Biologics, Intas Pharmaceuticals, Kashiv BioSciences, Merck KGaA, NeuClone, Nippon Kayaku, Novartis AG, Panacea Biotec, Pfizer Inc., Samsung Bioepis, Sanofi S.A., Shanghai Henlius Biotech, Teva Pharmaceutical Industries, Thermo Fisher Scientific, Apobiologix

Biosimilars Market: Key Takeaways

  • Biosimilars are shifting competitive dynamics in traditional biologics sectors as regulatory frameworks adapt to support faster approval and broader market entry.
  • Technological progress in cell lines, purification, and scalable production is lowering manufacturing costs and improving comparability, accelerating product launches in major therapeutic areas.
  • Strategic collaborations, including joint development, licensing, and contract manufacturing, are mitigating risks, reducing time to market, and facilitating regional launches.
  • Regional differences in reimbursement, switching policies, and payer engagement are shaping adoption rates and presenting both challenges and opportunities for targeted expansion.
  • Patient-centric approaches—such as simplified self-administration devices and support programs—are increasing biosimilar acceptance and adherence, particularly in ambulatory and homecare channels.
  • Advanced digital analytics and real-world evidence initiatives are supporting robust post-market surveillance and strengthening payer confidence in biosimilars.

Assessing the Impact of 2025 United States Tariffs

New US tariffs introduced in 2025 are altering supply chain strategies, prompting manufacturers to diversify sourcing and protect margins. The resulting import cost fluctuations are influencing procurement decisions and pricing discussions with major payers, creating a need for agile scenario planning. Pharmaceutical firms are increasingly exploring domestic sourcing, implementing multi-year supplier contracts, and conducting tariff sensitivity analyses to sustain competitiveness.

Methodology & Data Sources

This report synthesizes insights from primary interviews with industry leaders and regulatory specialists, as well as secondary data from journals, public filings, and proprietary records. Rigorous validation, including triangulation and anonymous peer review, ensures thorough and objective analysis of the evolving biosimilars landscape.

Why This Report Matters

  • Senior leaders can use this analysis to identify untapped opportunities in high-value therapeutic areas and design cost-efficient market entry strategies that reflect regional and regulatory nuances.
  • The insights support evidence-based decision-making on R&D investment, supply chain optimization, and cross-functional collaboration in a competitive biosimilars market.

Conclusion

Biosimilars are redefining value, accessibility, and competitive strategy in biopharma. Decision-makers equipped with targeted insights will be well-positioned to navigate regulatory complexity, respond to changing tariff landscapes, and capture sustainable market growth.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Regulatory alignment across regions accelerates approval pathways for complex biosimilars
5.2. Advanced cell line engineering drives cost-effective manufacturing of high-demand biosimilars
5.3. Surge in real-world evidence studies boosts clinician and payer confidence in biosimilar use
5.4. Emerging market expansions reshape global competition and pricing strategies for biosimilars
5.5. Interchangeability designations and pharmacist substitution laws transform biosimilar adoption
5.6. Digital health integrations support biosimilar pharmacovigilance and real world evidence generation at scale
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biosimilars Market, by Product Type
8.1. Introduction
8.2. Erythropoietin
8.3. Follitropin
8.4. Granulocyte-Colony Stimulating Factor (G-CSF)
8.5. Human Growth Hormone
8.6. Insulin
8.7. Interferons
8.8. Monoclonal Antibodies (mAbs)
9. Biosimilars Market, by Indication
9.1. Introduction
9.2. Autoimmune Diseases
9.3. Blood Disorders
9.4. Diabetes
9.5. Growth Hormone Deficiency
9.6. Infectious Diseases
9.7. Oncology
10. Biosimilars Market, by Administration Route
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Subcutaneous
11. Biosimilars Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Homecare
11.4. Hospitals
12. Americas Biosimilars Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Biosimilars Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Biosimilars Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Alvotech S.A
15.3.2. Amgen Inc.
15.3.3. Apotex Inc.
15.3.4. Biocon Limited
15.3.5. BioFactura, Inc.
15.3.6. Biogen Inc.
15.3.7. Boehringer Ingelheim International GmbH
15.3.8. Catalent, Inc
15.3.9. Celltrion Healthcare Co.,Ltd.
15.3.10. Coherus BioSciences
15.3.11. Dr. Reddy's Laboratories Limited
15.3.12. Eden Biologics, Inc.
15.3.13. F. Hoffmann-La Roche AG
15.3.14. Fresenius Kabi
15.3.15. Innovent Biologics, Inc.
15.3.16. Intas Pharmaceuticals Ltd.
15.3.17. Kashiv BioSciences, LLC.
15.3.18. Merck KGaA
15.3.19. NeuClone
15.3.20. Nippon Kayaku Co., Ltd.
15.3.21. Novartis AG
15.3.22. Panacea Biotec Limited
15.3.23. Pfizer Inc.
15.3.24. Samsung Bioepis Co., Ltd.
15.3.25. Sanofi S.A.
15.3.26. Shanghai Henlius Biotech, Inc.
15.3.27. Teva Pharmaceutical Industries Ltd.
15.3.28. Thermo Fisher Scientific, Inc.
15.3.29. Apobiologix
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BIOSIMILARS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. BIOSIMILARS MARKET: RESEARCHAI
FIGURE 24. BIOSIMILARS MARKET: RESEARCHSTATISTICS
FIGURE 25. BIOSIMILARS MARKET: RESEARCHCONTACTS
FIGURE 26. BIOSIMILARS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BIOSIMILARS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF), BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF), BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY HUMAN GROWTH HORMONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY HUMAN GROWTH HORMONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES (MABS), BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES (MABS), BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY DIABETES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BIOSIMILARS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BIOSIMILARS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BIOSIMILARS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BIOSIMILARS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BIOSIMILARS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BIOSIMILARS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BIOSIMILARS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BIOSIMILARS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 75. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 76. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 77. CANADA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 78. CANADA BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 79. CANADA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 80. CANADA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 81. CANADA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. CANADA BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 84. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 85. MEXICO BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 86. MEXICO BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 87. MEXICO BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 88. MEXICO BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 89. MEXICO BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. MEXICO BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 118. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 126. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 127. GERMANY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 128. GERMANY BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 129. GERMANY BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 130. GERMANY BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 131. GERMANY BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. GERMANY BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 134. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 135. FRANCE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 136. FRANCE BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 137. FRANCE BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 138. FRANCE BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 139. FRANCE BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. FRANCE BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. RUSSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 144. RUSSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 145. RUSSIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 146. RUSSIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 147. RUSSIA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. RUSSIA BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 150. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 151. ITALY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 152. ITALY BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 153. ITALY BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 154. ITALY BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 155. ITALY BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. ITALY BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 158. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 159. SPAIN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 160. SPAIN BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 161. SPAIN BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 162. SPAIN BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 163. SPAIN BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. SPAIN BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 174. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 176. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 178. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 182. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 186. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. DENMARK BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 190. DENMARK BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 191. DENMARK BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. DENMARK BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. DENMARK BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 194. DENMARK BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 195. DENMARK BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. DENMARK BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 198. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 199. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. NETHERLANDS BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 202. NETHERLANDS BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 203. NETHERLANDS BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. NETHERLANDS BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 206. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 207. QATAR BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. QATAR BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. QATAR BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 210. QATAR BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 211. QATAR BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. QATAR BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. FINLAND BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 214. FINLAND BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 215. FINLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 216. FINLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 217. FINLAND BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 218. FINLAND BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 219. FINLAND BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. FINLAND BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. SWEDEN BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 222. SWEDEN BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 223. SWEDEN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 224. SWEDEN BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 225. SWEDEN BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 226. SWEDEN BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 227. SWEDEN BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. SWEDEN BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. NIGERIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 230. NIGERIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 231. NIGERIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. NIGERIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. NIGERIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 234. NIGERIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 235. NIGERIA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. NIGERIA BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. EGYPT BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 238. EGYPT BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 239. EGYPT BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 240. EGYPT BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 241. EGYPT BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 242. EGYPT BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 243. EGYPT BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. EGYPT BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. TURKEY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 246. TURKEY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 247. TURKEY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. TURKEY BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. TURKEY BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 250. TURKEY BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 251. TURKEY BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. TURKEY BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. ISRAEL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 254. ISRAEL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 255. ISRAEL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. ISRAEL BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. ISRAEL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 258. ISRAEL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 259. ISRAEL BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. ISRAEL BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. NORWAY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. NORWAY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. NORWAY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 264. NORWAY BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 265. NORWAY BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 266. NORWAY BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 267. NORWAY BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. NORWAY BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. POLAND BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 270. POLAND BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 271. POLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. POLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. POLAND BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 274. POLAND BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 275. POLAND BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. POLAND BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. SWITZERLAND BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 278. SWITZERLAND BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 279. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 280. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 281. SWITZERLAND BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 282. SWITZERLAND BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 283. SWITZERLAND BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. SWITZERLAND BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 286. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 287. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 288. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 289. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 290. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 291. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 294. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 295. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 296. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 297. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 298. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 299. CHINA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 300. CHINA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 301. CHINA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. CHINA BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. INDIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 304. INDIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 305. INDIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 306. INDIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 307. INDIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 308. INDIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 309. INDIA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. INDIA BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. JAPAN BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 312. JAPAN BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 313. JAPAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 314. JAPAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 315. JAPAN BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 316. JAPAN BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 317. JAPAN BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 318. JAPAN BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 319. AUSTRALIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 320. AUSTRALIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 321. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 322. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 323. AUSTRALIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 324. AUSTRALIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 325. AUSTRALIA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. AUSTRALIA BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 328. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 329. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 330. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 331. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 332. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 333. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 334. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 335. INDONESIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 336. INDONESIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 337. INDONESIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 338. INDONESIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 339. INDONESIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 340. INDONESIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 341. INDONESIA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 342. INDONESIA BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 343. THAILAND BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 344. THAILAND BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 345. THAILAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 346. THAILAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 347. THAILAND BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 348. THAILAND BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 349. THAILAND BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 350. THAILAND BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 351. PHILIPPINES BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 352. PHILIPPINES BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 353. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 354. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 355. PHILIPPINES BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 356. PHILIPPINES BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 357. PHILIPPINES BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 358. PHILIPPINES BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 359. MALAYSIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 360. MALAYSIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 361. MALAYSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 362. MALAYSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 363. MALAYSIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 364. MALAYSIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 365. MALAYSIA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 366. MALAYSIA BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 367. SINGAPORE BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 368. SINGAPORE BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 369. SINGAPORE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 370. SINGAPORE BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 371. SINGAPORE BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 372. SINGAPORE BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 373. SINGAPORE BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 374. SINGAPORE BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE

Samples

Loading
LOADING...

Companies Mentioned

  • Alvotech S.A
  • Amgen Inc.
  • Apotex Inc.
  • Biocon Limited
  • BioFactura, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc
  • Celltrion Healthcare Co.,Ltd.
  • Coherus BioSciences
  • Dr. Reddy's Laboratories Limited
  • Eden Biologics, Inc.
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi
  • Innovent Biologics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Kashiv BioSciences, LLC.
  • Merck KGaA
  • NeuClone
  • Nippon Kayaku Co., Ltd.
  • Novartis AG
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Shanghai Henlius Biotech, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific, Inc.
  • Apobiologix

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 35.27 Billion
Forecasted Market Value ( USD ) by 2030 $ 60.6 Billion
Compound Annual Growth Rate11.3%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Biosimilar Monoclonal Antibodies Market by Molecule Class (Anti Cd20, Anti Her2, Anti Vascular Endothelial Growth Factor), Indication (Inflammatory Bowel Disease, Neutropenia, Oncology), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Biosimilar Monoclonal Antibodies Market by Molecule Class (Anti Cd20, Anti Her2, Anti Vascular Endothelial Growth Factor), Indication (Inflammatory Bowel Disease, Neutropenia, Oncology), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA - Product Image

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA

  • Report
  • 84 Pages
  • Global
From
Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035 - Product Image

Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035

  • Report
  • 392 Pages
  • Global
From
Biosimilars Market - Products, Applications and Regulations - Product Image

Biosimilars Market - Products, Applications and Regulations

  • Report
  • 227 Pages
  • Global
From
Biosimilars Market Report 2025 - Product Image

Biosimilars Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.